Background:
Hospice care relies heavily on parenteral opioids for symptom relief, but supply shortages or patients’ inability to tolerate oral and parenteral routes can limit access. The Macy catheter is a rectal catheter device that was FDA-approved in 2014. It offers an alternative method of administering oral medications via the rectal route. This method enables rapid absorption, effective symptom control, and can reduce the need for opioid titration or rotation.
Design and Participants:
In 2019, Ohio’s Hospice implemented and evaluated the Macy catheter across two affiliates serving 5,659 patients. A train-the-trainer program educated staff on use. One year after integration, a survey of 391 nurses was conducted, with 158 responses from inpatient and home care settings. Financial data comparing parenteral medication use and costs pre- and post-implementation were also collected.
Results:
- Nursing Survey (158 respondents):
- More effective than sublingual medications: 72%
- More comfortable than sublingual medications: 65%
- More effective than subcutaneous injections: 44%
- More comfortable than subcutaneous injections: 70%
- More effective at symptom management than expected: 67%
- Would recommend Macy catheter for hospice patients: 97%
- Financial Impact:
- Hydromorphone, methadone, and morphine vial use dropped significantly post-implementation.
- Annual cost savings: $13,992 in year 1 and $18,648 in year 2 compared to baseline.
- Case Study (48-year-old patient with metastatic colon cancer):
- Received large IV opioid doses without relief.
- After Macy catheter placement, achieved symptom relief within 20 minutes.
- Pain score dropped from 10 to 3, remained comfortable until death later that day.
Commentary:
The Macy catheter addresses key challenges in hospice and palliative care by offering an effective, rapid, and patient-friendly route for med delivery when oral or parenteral options are limited. Nursing acceptance was strong, and financial savings were significant. Wider adoption could support continuity of high-quality care during shortages and in patients with impaired oral or IV access. However, further study is warranted to evaluate long-term cost-benefit analysis and satisfaction across broader populations.
Bottom Line:
The Macy catheter is a cost-effective, nurse- and patient-accepted device that improves symptom management at end-of-life, reduces reliance on parenteral opioids, and offers a viable alternative route of medication administration.
Source:
Quinlin L, Schmitz W, Jefferson M. Macy Catheter: Integration and Evaluation in a Hospice Setting to Provide Symptom Relief During End-of-Life Care. Clin J Oncol Nurs. 2020 Dec 1;24(6):689-693. doi: 10.1188/20.CJON.689-693. PMID: 33216063.
Want to know more about our Palliative Care Education programs? Click below: